pharma · Age-related Macular Degeneration · Neovascular Age-related Macular Degeneration · OTLK
Outlook Therapeutics NL B. V.
Outlook Therapeutics NL drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Outlook Therapeutics NL drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
US regulatory status: approved. Mechanism: Unknown.
US regulatory status: approved. Molecular target: Cyclooxygenase.